drugset
drugset / Trial / NCT03623854

Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma

NCT03623854 ↗

Phase 2 Completed 10 enrolled Jonsson Comprehensive Cancer Center Bristol-Myers Squibb · collab
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial studies how well nivolumab and relatlimab work in treating participants with chordoma that has spread to other places in the body. Monoclonal antibodies, such as nivolumab and relatlimab, may interfere with the ability of tumor cells to grow and spread.

Timeline

Start
2019-04-03
Primary completion
2023-09-28
Completion
2023-09-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Nivolumab Monoclonal antibody — —
Subject Relatlimab Monoclonal antibody — Other

Indications

chordoma